TABLE 1.
Comparison of clinical characteristics of 76 continuous flow ventricular assist device recipients by use of chronic suppressive antibiotics
| Total (N ＝ 76） |
With CSA (N = 36) |
Without CSA (N = 40) |
P value | |
|---|---|---|---|---|
| Clinical characteristics | ||||
| Age, yearsa | 41 (34–50) | 44 (37–54) | 40 (28–50) | 0.08 |
| Male sex | 58 (76%) | 28 (78%) | 30 (75%) | 0.79 |
| Body mass indexa | 21 (18–24) | 21 (18–23) | 22 (19–25) | 0.42 |
| Alcohol use | 7 (9%) | 3 (8%) | 4 (10%) | 1.00 |
| Tobacco use | 23 (30%) | 11 (31%) | 12 (30%) | 1.00 |
| Etiology of heart failure | 0.46 | |||
| Ischemic cardiomyopathy | 7 (9%) | 2 (6%) | 5 (13%) | |
| Dilated cardiomyopathy | 57 (75%) | 27 (75%) | 30 (75%) | |
| Others | 12 (16%) | 7 (19%) | 5 (13%) | |
| Type of VAD | 0.09 | |||
| HeartMate II | 31 (41%) | 19 (53%) | 12 (30%) | |
| Jarvik 2000 | 17 (22%) | 9 (25%) | 8 (20%) | |
| DuraHeart | 13 (17%) | 4 (11%) | 9 (23%) | |
| EVAHEART | 15 (20%) | 4 (11%) | 11 (28%) | |
| Previous cardiac surgery | 34 (44%) | 19 (53%) | 15 (38%) | 0.25 |
| Cardiovascular implantable electronic device | 36 (47%) | 19 (53%) | 17 (43%) | 0.49 |
| Chronic kidney diseases and hemodialysis | 9 (12%) | 2 (6%) | 7 (18%) | 0.16 |
| Diabetes mellitus | 5 (7%) | 2 (6%) | 3 (8%) | 1.00 |
| Initial VAD infection | ||||
| Time from implantation to initial infection, daysa | 332 (75–534) | 368 (60–809) | 303 (162–403) | 0.54 |
| Classification of infection | 0.55 | |||
| VAD-specific infection | 63 (82%) | 31 (86%) | 32 (80%) | |
| Driveline infection | 58 | 29 | 29 | |
| Pump or cannula or pocket infection |
5 | 2 | 3 | |
| VAD-related infection | 13 (17%) | 5 (14%) | 8 (20%) | |
| Blood stream infection | 11 | 4 | 7 | |
| Mediastinitis | 2 | 1 | 1 | |
| Microbiology | <0.001 | |||
| Staphylococcus aureus | 48 (63%) | 32 (88%) | 16 (40%) | |
| Pseudomonas aeruginosa | 15 (20%) | 1 (3%) | 14 (35%) | |
| Others | 13 (17%) | 3 (8%) | 10 (25%) | |
| Surgical procedure at the time of initial infection | 24 (32%) | 12 (33%) | 12 (30%) | 0.81 |
| Duration of initial therapy (days) | 23.5 (13-43) | 21 (10–43) | 24 (16–48) | 0.45 |
a
Median (IQR).